Estados financieros detallados de Lisata Therapeutics, Inc. (LSTA): cuenta de resultados, balance general y flujo de caja. Sigue la evolución de márgenes, deuda, liquidez y rentabilidad año a año con hasta 20 años de histórico.
Resumen del Análisis
Márgenes de los últimos 12 meses: margen bruto 14.1%, margen operativo -107.1%, margen neto -97.6%.
Al precio actual de $1.47, LSTA presenta beneficios negativos (P/E no significativo) y un ROE del -111.65%. La capitalización bursátil es de $13M.
Cuenta de Resultados (10 años)
| Año | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| Ingresos | $35.3M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $1.0M | $170000 |
| Coste de Ventas | $450266 | $372000 | $225000 | $65000 | $63000 | 0 | 0 | 0 | 0 | $146000 |
| Beneficio Bruto | $4.1M | -$372000 | -$225000 | -$65000 | -$63000 | 0 | 0 | 0 | $1.0M | $24000 |
| I+D | $15.1M | $17.1M | $7.6M | $13.5M | $9.3M | $17.6M | $43.5M | $12.7M | $11.3M | $7.9M |
| Generales y Administrativos | $12.8M | $11.8M | $9.4M | $9.3M | $9.9M | $11.5M | $14.1M | $13.0M | $12.1M | $10.4M |
| Gastos Operativos | $35.5M | $27.6M | $17.0M | $20.1M | $19.1M | $29.1M | $57.6M | $25.7M | $23.4M | $18.2M |
| Beneficio Operativo | -$31.3M | -$27.6M | -$17.0M | -$20.1M | -$19.1M | -$29.1M | -$57.6M | -$25.7M | -$22.4M | -$18.2M |
| EBITDA | -$29.0M | -$27.2M | -$16.8M | -$20.0M | -$19.1M | -$28.9M | -$56.6M | -$23.0M | -$20.6M | -$17.4M |
| Gastos por Intereses | $1.9M | $377768 | $5000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Beneficio Antes de Impuestos | -$31.3M | -$27.7M | -$16.2M | -$19.4M | -$19.0M | -$29.0M | -$56.7M | -$23.2M | -$20.8M | -$17.5M |
| Impuestos | $138038 | -$11.5M | -$1000 | 0 | -$10.9M | -$1.5M | -$2.5M | -$2.3M | -$798000 | -$962000 |
| Beneficio Neto | -$32.7M | $23.0M | -$16.2M | -$20.1M | -$8.2M | -$27.5M | -$54.2M | -$20.8M | -$20.0M | -$16.6M |
| BPA | $-74.81 | $38.43 | $-25.03 | $-29.20 | $-7.91 | $-7.45 | $-10.47 | $-2.58 | $-2.40 | $-1.91 |
| BPA Diluido | $-74.81 | $38.43 | $-25.03 | $-29.20 | $-7.91 | $-7.45 | $-10.47 | $-2.58 | $-2.40 | $-1.91 |
| Acciones en Circulación (Diluidas) | $436550 | $597933 | $645933 | $688333 | $1.0M | $3.7M | $5.2M | $8.1M | $8.3M | $8.7M |
Cuenta de Resultados (Trimestral)
| Año | 2025-Q3 | 2025-Q4 | 2026-Q1 | 2026-Q2 |
|---|
| Ingresos | 0 | $100000 | 0 | 0 |
| Beneficio Bruto | 0 | $100000 | -$2000 | -$3000 |
| Beneficio Operativo | -$4.4M | -$3.1M | -$4.9M | -$4.0M |
| EBITDA | -$4.2M | -$2.9M | -$4.9M | -$4.0M |
| Beneficio Neto | -$4.2M | -$3.0M | -$4.5M | -$2.9M |
| BPA | $-0.49 | $-0.33 | $-0.50 | $-0.32 |
| BPA Diluido | $-0.49 | $-0.33 | $-0.50 | $-0.32 |
Balance (10 años)
| Año | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| Caja y Equivalentes | $14.7M | $29.2M | $10.3M | $14.0M | $16.5M | $24.6M | $32.2M | $22.6M | $16.2M | $16.0M |
| Inversiones a Corto | 0 | $25.9M | $32.8M | $11.1M | $18.1M | $70.3M | $37.1M | $27.9M | $15.0M | 0 |
| Cuentas por Cobrar | $138774 | $234461 | 0 | 0 | 0 | 0 | 0 | 0 | $900000 | $700000 |
| Inventario | $3.6M | $5.0M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Activos Corrientes | $24.6M | $61.1M | $44.1M | $26.0M | $35.3M | $96.2M | $71.9M | $53.9M | $34.6M | $17.7M |
| Inmovilizado Material | $17.1M | $256900 | $165000 | $100000 | $57000 | $62000 | $296000 | $175000 | $72000 | $18000 |
| Fondo de Comercio | $7.0M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Activos Intangibles | $2.3M | 0 | 0 | 0 | 0 | 0 | $334000 | $263000 | $192000 | 0 |
| Activos Totales | $51.8M | $63.4M | $44.6M | $27.2M | $36.0M | $97.0M | $73.0M | $54.7M | $35.0M | $17.7M |
| Cuentas por Pagar | $2.2M | $1.3M | $762000 | $1.5M | $1.0M | $1.9M | $2.7M | $2.4M | $1.3M | $1.0M |
| Deuda a Corto | $3.7M | $159000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Pasivos Corrientes | $19.5M | $9.3M | $5.6M | $6.0M | $3.5M | $4.5M | $6.4M | $6.6M | $5.6M | $3.1M |
| Deuda a Largo | $2.7M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Pasivos Totales | $47.8M | $13.2M | $7.1M | $6.6M | $3.8M | $5.0M | $6.7M | $6.8M | $5.7M | $3.1M |
| Reservas | -$404.8M | -$381.8M | -$398.0M | -$417.4M | -$425.6M | -$453.0M | -$507.2M | -$528.1M | -$548.1M | -$564.7M |
| Patrimonio Neto | $4.9M | $50.5M | $37.7M | $20.8M | $32.5M | $92.3M | $66.6M | $48.1M | $29.6M | $14.9M |
| Deuda Total | $6.8M | $159180 | 0 | $978000 | $624000 | $714000 | $485000 | $168000 | $137000 | 0 |
| Deuda Neta | -$7.9M | -$54.9M | -$43.1M | -$24.2M | -$33.9M | -$94.3M | -$68.7M | -$50.4M | -$31.1M | -$16.0M |
| Capital Circulante | $5.1M | $51.8M | $38.5M | $20.0M | $31.8M | $91.7M | $65.5M | $47.3M | $29.0M | $14.6M |
Balance (Trimestral)
| Año | 2025-Q3 | 2025-Q4 | 2026-Q1 | 2026-Q2 |
|---|
| Caja y Equivalentes | $19.0M | $16.0M | $13.1M | $10.4M |
| Activos Totales | $21.8M | $17.7M | $14.1M | $11.0M |
| Pasivos Totales | $4.6M | $3.1M | $3.4M | $3.0M |
| Patrimonio Neto | $17.4M | $14.9M | $10.9M | $8.2M |
| Deuda Total | 0 | 0 | 0 | 0 |
Flujo de Caja (10 años)
| Año | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| Beneficio Neto | -$33.3M | -$16.2M | -$16.2M | -$19.4M | -$8.1M | -$27.5M | -$54.2M | -$20.8M | -$20.0M | -$16.6M |
| Amortizaciones | $2.7M | $372000 | $225000 | $65000 | $63000 | $55000 | $69000 | $189000 | $174000 | $146000 |
| Compensación en Acciones | $2.6M | $2.0M | $2.5M | $1.3M | $1.3M | $2.0M | $2.6M | $2.0M | $1.7M | $1.2M |
| Cambio en Capital Circulante | $3.6M | $5.1M | -$5.3M | -$1.1M | -$2.3M | $647000 | -$831000 | -$462000 | -$873000 | -$1.3M |
| Flujo de Caja Operativo | -$23.7M | -$20.9M | -$20.0M | -$18.9M | -$8.8M | -$22.2M | -$21.2M | -$20.0M | -$19.4M | -$15.9M |
| Inversiones (CapEx) | -$2.8M | -$135281 | -$134000 | 0 | -$20000 | -$60000 | -$285000 | 0 | 0 | -$28000 |
| Adquisiciones | 0 | $67.9M | $2.5M | 0 | $7257 | $54836 | -$3.3M | 0 | -$130000 | 0 |
| Recompra de Acciones | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividendos Pagados | -$15.0M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Flujo de Caja Libre | -$26.5M | -$21.0M | -$20.1M | -$18.9M | -$8.8M | -$22.3M | -$21.5M | -$20.0M | -$19.4M | -$16.0M |
Flujo de Caja (Trimestral)
| Año | 2025-Q3 | 2025-Q4 | 2026-Q1 | 2026-Q2 |
|---|
| Flujo de Caja Operativo | -$3.3M | -$3.2M | -$3.1M | -$2.6M |
| Inversiones (CapEx) | 0 | 0 | 0 | 0 |
| Flujo de Caja Libre | -$3.3M | -$3.2M | -$3.1M | -$2.6M |
| Dividendos Pagados | 0 | 0 | 0 | 0 |
| Compensación en Acciones | $232000 | $225000 | $364000 | $214000 |
Crecimiento y Márgenes (10 años)
| Año | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| Crecimiento Ingresos (anual) | | -100.0% | | | | | | | | -83.0% |
| Crecimiento Beneficio Neto (anual) | | +170.4% | -170.4% | -24.3% | +59.5% | -237.0% | -97.4% | +61.6% | +4.1% | +17.0% |
| Crecimiento BPA (anual) | | +151.4% | -165.1% | -16.7% | +72.9% | +5.8% | -40.5% | +75.4% | +7.0% | +20.4% |
| Cambio en Acciones (anual) | | +37.0% | +8.0% | +6.6% | +49.5% | +258.4% | +40.5% | +55.8% | +3.2% | +4.3% |
| Crecimiento FCF (anual) | | +20.8% | +4.2% | +6.2% | +53.2% | -152.2% | +3.8% | +6.6% | +3.4% | +17.5% |
| Margen Bruto | 11.8% | | | | | | | | 100.0% | 14.1% |
| Margen Operativo | -88.8% | | | | | | | | -2240.9% | -10711.2% |
| Margen EBITDA | -82.3% | | | | | | | | -2060.9% | -10236.5% |
| Margen Neto | -92.6% | | | | | | | | -1998.5% | -9756.5% |
| Margen FCF | -75.2% | | | | | | | | -1935.6% | -9398.2% |
| Tasa Impositiva Efectiva | -0.4% | 41.6% | 0.0% | -0.0% | 57.2% | 5.2% | 4.4% | 10.1% | 3.8% | 5.5% |
Datos por Acción (10 años)
| Año | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| FCF por Acción | $-60.74 | $-35.14 | $-31.15 | $-27.43 | $-8.59 | $-6.05 | $-4.14 | $-2.48 | $-2.32 | $-1.84 |
| Dividendo por Acción | $34.36 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Acciones en Circulación (Básicas) | $436550 | $597933 | $645933 | $688333 | $1.0M | $3.7M | $5.2M | $8.1M | $8.3M | $8.7M |
Qué mirar en Biotech
La mayoría de biotechs pequeñas pierden dinero. Analizarlas con P/E no tiene sentido — mira caja y pipeline.
- Cash Runway — Meses de caja al ritmo de gasto actual. <18 meses = riesgo de dilución urgente
- Cash burn anual — Ritmo al que queman caja operativa. Comparar con posición de caja para proyectar runway
- Total Debt — Biotech sin ingresos + deuda = receta para bancarrota
- I+D / Capitalización — Cuánto invierten en pipeline vs lo que vale la empresa — indicador de intensidad investigadora
- Market cap / Cash — Si cotiza cerca de su caja, el mercado le da ~0 valor al pipeline — puede ser oportunidad o trampa
Rentabilidad
| Rentabilidad sobre capital | -111.65% |
| Rentabilidad sobre capital invertido | -117.30% |
| Rentabilidad sobre activos | -93.47% |
| Margen bruto | 14.12% |
| Margen operativo | -10711.18% |
| Margen neto | -9756.47% |
Salud financiera
| Deuda / Patrimonio | 0.00 |
| Ratio corriente | 5.76 |
Ratios Clave (10 años)
| Año | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| P/E | -0.57 | 1.44 | -2.13 | -1.29 | -2.71 | -1.69 | -0.24 | -1.06 | -1.24 | -0.97 |
| P/VC | 3.79 | 0.66 | 0.91 | 1.24 | 0.68 | 0.50 | 0.20 | 0.46 | 0.84 | 1.09 |
| P/V | 0.53 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 24.82 | 95.05 |
| Margen Bruto | 11.8% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 100.0% | 14.1% |
| Margen Operativo | -88.8% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | -2240.9% | -10711.2% |
| Margen Neto | -92.6% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | -1998.5% | -9756.5% |